ArticleBMC public health2025
Global trends and regional differences of hepatoblastoma: a systematic analysis and predictions to 2035 based on the global burden of disease study 2021.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Bibliometric and clinical trial landscape of hepatoblastoma (2000-2024): a multi-database analysis of global research.Frontiers in oncology · 2026Pooled it
- Parental and childhood exposures and the risk of retinoblastoma, hepatoblastoma, and germ cell, bone, and soft tissue tumors in children: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Pediatric Hepatoblastoma: From Developmental Molecular Mechanisms to Innovative Therapeutic Strategies.Cancers · 2026Review
- Treatment and outcomes of hepatoblastoma in a tertiary care pediatric institution: a single-center experience.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatoblastoma accounts for the majority of liver malignancies in children with a high socioeconomic burden worldwide. Comprehensive and accurate burden data assessment is crucial for health policy planning. MATERIALS AND
methodsEpidemiological data of hepatoblastoma was extracted from the Global Burden of Diseases Study 2021. The incidence, prevalence, mortality, and disability-adjusted life years (DALYs) were assessed and Joinpoint regression analysis was conducted to evaluate the time trends. Age-standardized rates (ASR) were used to compare the burden among different sociodemographic index (SDI) and GBD regions. The Bayesian age-period-cohort model was applied to predict the disease burden.
resultsIn 2021, there were 4048.42 new cases (95% UI: 3252.45-5000.45) and 2416.17 deaths (95% UI: 1922.47-3019.03) worldwide, of which 35.0% of new cases and 40.9% of deaths occurred in low SDI countries, and the corresponding ASR of morbidity and mortality was 0.09 (95% UI: 0.06-0.12) and 0.06 (95% UI: 0.04-0.08). Western Sub-Saharan contributed the highest ASR of incidence (0.10) and death (0.07) across the 21 GBD regions. The morbidity (1.23) and mortality rate (0.74) of the under 1 year-old group were higher than those of other age groups. Compared with 1990, the incidence, mortality, and DALYs of hepatoblastoma decreased significantly, with estimated annual percentage change (EAPC) of -2.03, -2.54, and - 2.53. The high SDI regions exhibited an upward trend in incidence with EAPC of 0.73. Joinpoint regression analysis indicated a gradual but fluctuating decline in ASR of incidence, prevalence, death and DALYs. The global burden was predicted to decrease while an increased incidence and mortality in low SDI countries.
conclusionThe morbidity and mortality burden of hepatoblastoma has steadily decreased over the last 31 years. However, the increased incidence in high SDI areas and the higher mortality in low SDI areas pose a significant challenge. Effective differentiated intervention should be facilitated to reduce the impact of hepatoblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.